Ruxolitinib's FDA Approval Timeline
Ruxolitinib (Jakafi), developed by Incyte and Novartis, received FDA approval for myelofibrosis in November 2011 after priority review, with no public reports of delays tied to data integrity issues in its pivotal trials (COMFORT-I and COMFORT-II). The NDA submission occurred in late 2010, and approval came within about 10 months—faster than the standard 10-12 months for standard review.[1]
Any Reported Data Integrity Problems?
No unique data integrity challenges appear in FDA reviews, warning letters, or public records for ruxolitinib's original approval. The FDA's multi-discipline review praised the submitted data for demonstrating "substantial evidence of efficacy" with manageable safety signals, like anemia and infections. Post-approval, Incyte faced a 2013 FDA warning letter for manufacturing issues at a contract site (cGMP violations, not clinical data), but this did not impact prior approval or label expansions.[2][3]
What Caused Any Perceived Delays?
Any timeline perceptions may stem from:
- Phase 3 trial duration: COMFORT trials ran from 2007-2010, typical for orphan diseases like myelofibrosis.
- Label expansions: Later approvals (e.g., polycythemia vera in 2014, graft-vs-host disease in 2019) followed standard timelines without data flags.
- No litigation or holds: Unlike some oncology drugs, ruxolitinib avoided clinical holds or integrity probes.
Manufacturing fixes were required post-approval but did not retroactively question trial data integrity.
Patent and Exclusivity Status
Ruxolitinib's key composition-of-matter patent (US 7,598,257) expires in 2027, with pediatric exclusivity to November 2027. No challenges cite data integrity; disputes focus on formulation and method-of-use patents.[4]
[1]: FDA Approval Letter for Jakafi (ruxolitinib)
[2]: FDA Multi-Discipline Review for Jakafi
[3]: FDA Warning Letter to Incyte (2013)
[4]: DrugPatentWatch.com - Ruxolitinib Patents